Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Last trade$1.17
Day change+$0.015 (+1.30%)
Day range$1.15 – $1.22
Volume493,549
Market cap$95M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$94.67M
Price / earnings
—
Price / book
1.8×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.1×
Profitability
Earnings per share
-$0.22
Return on assets
-32.89%
Return on equity
-34.84%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
19.49×
Quick ratio
19.49×
Cash ratio
18.92×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.48M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EQ, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$4.39M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$4.39M
Selling, general and administrative
$2.56M
$2.41M
$2.62M
$2.43M
$3.27M
$2.15M
$2.95M
$1.78M
Research and development
$2.49M
$2.75M
$2.99M
$1.54M
$1.3M
$4.08M
$5.92M
$7.32M
Total operating expenses
$5.05M
$5.16M
$5.61M
$3.96M
$4.58M
$6.23M
$8.87M
$9.09M
Operating income
-$5.05M
-$5.16M
-$5.61M
-$3.96M
-$4.58M
-$6.23M
-$8.87M
-$4.7M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.58M
-$4.69M
-$5.31M
-$3.78M
-$4.23M
-$5.74M
-$8.65M
-$5.43M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$361K
Net income
-$4.58M
-$4.69M
-$5.31M
-$3.78M
-$4.23M
-$5.74M
-$8.65M
-$5.79M
Net income attributable to common shareholders
-$4.58M
-$4.69M
-$5.3M
-$3.78M
-$4.23M
-$5.74M
-$8.7M
-$5.79M
EBITDA
-$5.02M
-$5.13M
-$5.59M
-$3.94M
-$4.55M
-$6.2M
-$8.84M
-$4.66M
Basic earnings per share
-$0.04
-$0.04
-$0.06
-$0.04
-$0.06
-$0.16
-$0.24
-$0.16
Diluted earnings per share
-$0.04
-$0.04
-$0.06
-$0.04
-$0.06
-$0.16
-$0.24
-$0.17
Recent news
Company coverage with links to the original publishers.
Wereldhave Belgium has acquired a supermarket anchor unit in shopping center Ville2 in Charleroi, achieving 100% ownership of the property. The acquisition was financed through newly issued Wereldhave N.V. shares at market value and will have a slightly positive impact on the group's LTV ratio, reducing it by 10 basis points to 42.4%.
Equillium will host a virtual key opinion leader event discussing unmet needs in ulcerative colitis treatment, featuring experts who will explore the potential of AhR modulation and the company's EQ504 therapeutic approach.
Five Nasdaq-listed stocks significantly outperformed the index in August, with gains ranging from 188% to 378%, driven by factors like drug development progress, FDA approvals, and strategic partnerships.
The graft versus host disease market is experiencing significant growth, driven by the adoption of branded therapies, a strong pipeline with the anticipated launch of over 10 new drugs, and increased awareness of GvHD management. Innovative treatments and ongoing research are expected to further expand market opportunities.
Vivtex and Equillium have entered a research collaboration to develop an optimized oral version of Equillium's EQ302, a bi-specific peptide inhibitor of IL-15 and IL-21, for the treatment of gastrointestinal disorders.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jun 12, 2009
$0.6875
Jun 30, 2009
recurring
Mar 13, 2009
$0.6875
Mar 31, 2009
recurring
Dec 8, 2008
$0.6875
Dec 31, 2008
recurring
Sep 5, 2008
$0.6875
Sep 30, 2008
recurring
Jun 5, 2008
$0.6875
Jun 30, 2008
recurring
Stock splits
Historical share-structure events and their execution dates.